Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 151 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Agitated Behavior Clear all
Completed Phase 3 Interventional Results available

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

NCT01862640
View directory record Official record
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712, Placebo Oral Tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

NCT04010305
View directory record Official record
Conditions
Agitation, Schizophrenia
Interventions
Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 10:19 PM EDT
Terminated Phase 3 Interventional

Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia

NCT00315900
View directory record Official record
Conditions
Agitation, Dementia
Interventions
Depakote ER, Seroquel
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 24, 2026, 10:19 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

NCT03110900
View directory record Official record
Conditions
Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions
Haloperidol + lorazepam, Loxapine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Not applicable Interventional Results available

Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

NCT01126099
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Prazosin, Placebo
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 24, 2026, 10:19 PM EDT
Terminated Phase 2 Interventional Results available

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

NCT05276830
View directory record Official record
Conditions
Agitation, Dementia
Interventions
BXCL501, Placebo film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
65 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
North Miami, Florida • Springfield, Massachusetts • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients

NCT02612948
View directory record Official record
Conditions
Psychomotor Agitation
Interventions
Quetiapine
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 24, 2026, 10:19 PM EDT
Active, not recruiting Phase 3 Interventional

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

NCT05397639
View directory record Official record
Conditions
Agitation, Alzheimer's Type Dementia
Interventions
Masupirdine 50 mg, Masupirdine 100 mg, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
50 Years to 90 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Anaheim, California • Costa Mesa, California • Encino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Results available

Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure

NCT02203019
View directory record Official record
Conditions
Sepsis, Respiratory Failure, Agitation
Interventions
Propofol, Dexmedetomidine, Fentanyl
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Not applicable Interventional

Bathing Persons With Alzheimer's Disease aT Home (The BATH Study)

NCT00062569
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bathing Support Intervention (BSI), Caregiver reminiscence with coaching
Behavioral
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
60 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Not applicable Interventional Results available

Alzheimer's in Long-Term Care--Treatment for Agitation

NCT00161473
View directory record Official record
Conditions
Alzheimer Disease, Psychomotor Agitation
Interventions
prazosin, placebo (inert substance)
Drug
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 24, 2026, 10:19 PM EDT
Terminated Phase 2 Interventional Results available

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

NCT03044249
View directory record Official record
Conditions
Psychosis, Dementia, Aggression, Agitation, Alzheimer Dementia
Interventions
MP-101, Placebo
Drug
Lead sponsor
Mediti Pharma Inc.
Other
Eligibility
50 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Pasadena, California • Fairfield, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Not applicable Interventional

Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations

NCT02613052
View directory record Official record
Conditions
Transesophageal Echocardiography Contrast Agents
Interventions
normal saline, human albumin, human albumin and propofol
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

NCT03548584
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
Interventions
Brexpiprazole, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Not applicable Interventional

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

NCT03926520
View directory record Official record
Conditions
Alzheimer Dementia, Agitation,Psychomotor
Interventions
Electroconvulsive Therapy (ECT)
Device
Lead sponsor
Brent Forester
Other
Eligibility
40 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Belmont, Massachusetts • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methodology Issues in a Tailored Light Treatment for Persons With Dementia

NCT01816152
View directory record Official record
Conditions
Sleep Disturbances, Depression
Interventions
High Active intervention, Inactive intervention, Mid Level Active Intervention
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Albany, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

NCT00843518
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY451395, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Phoenix, Arizona • Costa Mesa, California • Hamden, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium

NCT00351299
View directory record Official record
Conditions
Delirium, Agitation
Interventions
Dexmedetomidine, Standard of Care
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Healing Touch on Post Operative Pediatric Patients

NCT01738308
View directory record Official record
Conditions
Surgery, Stress, Pain, Children, Post-Traumatic Stress Disorder
Interventions
Healing Touch, Healing Touch Sham Treatment
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 4 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02442765
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
111
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Healthy Patterns Sleep Study

NCT03682185
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder, Insomnia, Hypersomnia, Cognitive Impairment, Cognitive Decline, Mild Cognitive Impairment, Frontotemporal Dementia, Neurocognitive Disorders, Vascular Dementia, Sleep Disorder, Memory Impairment
Interventions
Attention-Control Condition, Timed Activity Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
421 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 24, 2026, 10:19 PM EDT
Completed Phase 4 Interventional

Escitalopram Treatment of Patients With Agitated Dementia

NCT00260624
View directory record Official record
Conditions
Alzheimer's Disease, Psychomotor Agitation
Interventions
Escitalopram (Lexapro)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
61 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Fairport, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 24, 2026, 10:19 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep

NCT07061470
View directory record Official record
Conditions
ADHD, Sleep Problems
Interventions
Ferrous Sulfate, Placebo
Dietary Supplement · Other
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 24, 2026, 10:19 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants

NCT01360450
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine HCL, saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Days to 90 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 24, 2026, 10:19 PM EDT